<DOC>
	<DOCNO>NCT02580955</DOCNO>
	<brief_summary>A physician initiate trial investigate LEGFLOW Paclitaxel-Eluting Peripheral Balloon dilatation catheter treatment femoropopliteal lesion longer 15cm . Objective : evaluate short-term outcome treatment mean LEGFLOW Paclitaxel-Eluting Peripheral BAlloon Dilattaion treatment long femoropopliteal lesion ( TASC C &amp; D ) .</brief_summary>
	<brief_title>REFLOW Study , Investigating Efficacy LEGFLOW DCB TASC C &amp; D Fempop Lesions</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Patient present score 2 5 follow Rutherford classification 2 . Patient willing comply specify followup evaluation specify time 3 . Patient &gt; 18 year old 4 . Patient understands nature procedure provide write informed consent , prior enrolment study 5 . Patient project life expectancy least 12 month 6 . Prior enrolment , guidewire cross target lesion 7 . Patient eligible treatment LEGFLOW PaclitaxelEluting Peripheral Balloon Dilatation Catheter 8 . Male , infertile female female child bear potential practicing acceptable method birth control negative pregnancy test within 7 day prior study procedure 9 . De novo lesion locate femoropopliteal artery suitable endovascular therapy 10 . The target lesion locate within native femoropopliteal artery 11 . The length target lesion &gt; 150mm consider TASC C D lesion accord TASC II classification . 12 . The target lesion angiographic evidence stenosis &gt; 50 % occlusion pass standard guidewire manipulation 13 . Target vessel diameter visually estimate &gt; 4mm &lt; 6.5 mm 14 . There angiographic evidence least onevesselrunoff foot , irrespective whether outflow reestablish mean previous endovascular intervention 1 . Patient refuse treatment 2 . Presence stent target lesion place previous procedure 3 . Untreated flowlimiting inflow lesion 4 . Any previous surgery target vessel ( include prior ipsilateral crural bypass ) 5 . Presence aortic thrombosis significant common femoral ipsilateral stenosis 6 . Previous bypass surgery limb 7 . Patients antiplatelet therapy , anticoagulant thrombolytic drug contraindicate 8 . Patients exhibit persistent acute intraluminal thrombus propose lesion site 9 . Perforation angioplasty site evidence extravasation contrast medium 10 . Patients know hypersensitivity heparin , include patient previous incidence heparininduced thrombocytopenia ( HIT ) type II 11 . Patients uncorrected bleed disorder 12 . Aneurysm locate level SFA 13 . Nonatherosclerotic disease result occlusion ( e.g . embolism , Buerger 's disease , vasculitis ) 14 . Severe medical comorbidities ( untreated CAD/CHF , sever COPD , metastatic malignancy , dementia , etc . ) medical condition would preclude compliance study protocol 1year life expectancy 15 . Major distal amputation ( transmetatarsal ) study limb nonstudy limb 16 . Septicemia bacteremia 17 . Ipsilateral iliac treatment target lesion procedure residual stenosis &gt; 30 % ipsilateral iliac treatment conduct target lesion procedure 18 . Use thrombectomy , atherectomy laser device procedure 19 . Any patient consider hemodynamically unstable onset procedure 20 . Known allergy contrast medium adequately premedicated prior study procedure 21 . Patient currently participate another investigational drug device study complete entire follow period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>